Delivery of antiemetics through an inhalation route
First Claim
1. A condensation aerosol for delivery of dolasetron formed by heating a composition containing dolasetron coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of dolasetron and less than 5 percent by weight of dolasetron degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiemetic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antiemetic degradation products. In a kit aspect of the present invention, a kit for delivering an antiemetic through an inhalation route is provided which comprises: a) a thin layer of an antiemetic drug and b) a device for dispensing said thin layer an antiemetic as a condensation aerosol.
-
Citations
38 Claims
- 1. A condensation aerosol for delivery of dolasetron formed by heating a composition containing dolasetron coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of dolasetron and less than 5 percent by weight of dolasetron degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 4. A condensation aerosol for delivery of granisetron formed by heating a composition containing granisetron coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of granisetron and less than 5 percent by weight of granisetron degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 7. A condensation aerosol for delivery of metoclopramide formed by heating a composition containing metoclopramide coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of metoclopramide and less than 5 percent by weight of metoclopramide degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
-
10. A method of forming a dolasetron containing aerosol comprising:
-
(a) heating a composition containing dolasetron coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of dolasetron degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (11, 12, 28)
-
-
13. A method of forming a granisetron containing aerosol comprising:
-
(a) heating a composition containing granisetron coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of granisetron degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (14, 15, 29)
-
-
16. A method of forming a metoclopramide containing aerosol comprising:
-
(a) heating a composition containing metoclopramide coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of metoclopramide degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (17, 18, 30)
-
-
19. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of dolasetron, granisetron, and metoclopramide, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (20, 21, 31)
-
-
22. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of dolasetron, granisetron, and metoclopramide, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (23, 24, 32)
-
-
33. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of dolasetron, granisetron, and metoclopramide, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (34, 35, 36, 37, 38)
-
Specification